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Abstract
Deriving disease subtypes from electronic health records (EHRs) can guide next-generation person-
alized medicine. However, challenges in summarizing and representing patient data prevent widespread
practice of scalable EHR-based stratification analysis. Here we present an unsupervised framework based
on deep learning to process heterogeneous EHRs and derive patient representations that can efficiently
and effectively enable patient stratification at scale. We considered EHRs of 1, 608, 741 patients from
a diverse hospital cohort comprising of a total of 57, 464 clinical concepts. We introduce a representa-
tion learning model based on word embeddings, convolutional neural networks, and autoencoders (i.e.,
ConvAE) to transform patient trajectories into low-dimensional latent vectors. We evaluated these rep-
resentations as broadly enabling patient stratification by applying hierarchical clustering to different
multi-disease and disease-specific patient cohorts. ConvAE significantly outperformed several baselines
in a clustering task to identify patients with different complex conditions, with 2.61 entropy and 0.31
purity average scores. When applied to stratify patients within a certain condition, ConvAE led to
various clinically relevant subtypes for different disorders, including type 2 diabetes, Parkinson’s disease
and Alzheimer’s disease, largely related to comorbidities, disease progression, and symptom severity.
With these results, we demonstrate that ConvAE can generate patient representations that lead to clin-
ically meaningful insights. This scalable framework can help better understand varying etiologies in
heterogeneous sub-populations and unlock patterns for EHR-based research in the realm of personalized
medicine.
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Introduction
Electronic health records (EHRs) are collected as part of routine care across the vast majority of healthcare
institutions. They consist of heterogeneous structured and unstructured data elements, including demo-
graphic information, diagnoses, laboratory results, medication prescriptions, free text clinical notes, and
images. EHRs provide snapshots of a patient’s state of health and have created unprecedented opportunities
to investigate the properties of clinical events across large populations using data-driven approaches and
machine learning. At the individual level, patient trajectories can foster personalized medicine; across a
population, EHRs can provide a vital resource to understand population health management and help make
better decisions for healthcare operation policies [1].
Personalized medicine focuses on the use of patient-specific data to tailor treatment to an individual’s
unique health characteristics. However, even seemingly simple diseases can show different degrees of com-
plexity that can create challenges for identification, treatment, and prognosis, despite equivalence at the
diagnostic level [2, 3]. Heterogeneity among patients is particularly evident for complex disorders, where the
etiology is due to an amalgamation of multiple genetic, environmental, and lifestyle factors. Several different
conditions have been referred to as complex, such as Parkinson’s disease (PD) [4], multiple myeloma (MM)
[5], and type 2 diabetes (T2D) [6]. Patients with complex disorders may differ on multiple systemic layers
(e.g., different clinical measurements or comorbidity landscape) and in response to treatments, making these
conditions difficult to model. Multiple data types in patient longitudinal EHR histories offer a way to exam-
ine disease complexity and present an opportunity to refine diseases into subtypes and tailor personalized
treatments. This task is usually referred to as “EHR-based patient stratification”. This follows a common
approach in clinical research, where attempts to identify latent patterns within a cohort of patients can
contribute to the development of improved personalized therapies [7].
From a computational perspective, patient stratification is a data-driven, unsupervised learning task that
groups patients according to their clinical characteristics [8]. Previous work in this domain aggregates clinical
data at a patient level, representing each patient as multi-dimensional vectors, and derives subtypes within
a disease-specific population via clustering (e.g., in autism [9]) or topological analysis (e.g., for T2D [10]).
Deep learning has been applied to derive more robust patient representations to improve disease subtyping
[8, 11]. Baytas et al. used time-aware long short-term memory (LSTM) networks to leverage stratification
of longitudinal data of PD patients [8]. Similarly, Zhang et al. used LSTM to identify three subgroups of
patients with idiopathic PD that differ in disease progression patterns and symptom severity [11]. These
studies, however, only focused on curated and small disease-specific cohorts, with ad hoc manually selected
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features. This approach not only limits scalability and generalizability, but also hinders the possibility
to discover unknown patterns that might characterize a condition. Because EHRs tend to be incomplete,
using a diverse cohort of patients to derive disease-specific subgroups can adequately capture the features of
heterogeneity within the disease of interest [12]. However, it is challenging to create large-scale computational
models from EHRs because of data quality issues, such as high dimensionality, heterogeneity, sparseness,
random errors, and systematic biases. Advances in machine learning, specifically in representation learning
[13] and deep learning [14], are introducing different computational models to leverage EHRs for personalized
healthcare [15, 16]. This work fits into this landscape by presenting an unsupervised patient stratification
pipeline that aims to automatically detect clinically meaningful subtypes within any condition by using
patient representations learned from a heterogeneous and large cohort of EHRs.
In particular, this paper proposes a general framework for identifying disease subtypes at scale (see
Figure 1a). We first propose an unsupervised deep learning architecture to derive vector-based patient
representations from a large and domain-free collection of EHRs. This model (i.e., ConvAE) combines 1)
embeddings to contextualize medical concepts, 2) convolutional neural networks (CNNs) to loosely model the
temporal aspects of patient data, and 3) autoencoders (AEs) to enable the application of an unsupervised
architecture. Second, we show that ConvAE-based representations learned from real-world EHRs of about
1.6M patients from the Mount Sinai Health System in New York improve clustering of patients with different
disorders compared to several commonly used baselines. Last, we demonstrate that ConvAE leads to effective
patient stratification with minimal effort. To this end, we used the encodings learned from domain-free and
heterogeneous EHRs to derive subtypes for different complex disorders and provide a qualitative analysis to
determine their clinical relevance.
This architecture enables patient stratification at scale by eliminating the need for manual feature engi-
neering and explicit labeling of events within patient care timelines, and processes the whole EHR sequence
regardless of the length of patient history. By generating disease subgroups from large-scale EHR data, this
architecture can help disentangle clinical heterogeneity and identify high-impact patterns within complex
disorders, whose effect may be masked in case-control studies [17]. The specific properties of the different
subgroups can then potentially inform personalized treatments and improve patient care.
Results
We first evaluated the extent to which ConvAE-based patient representations can be used to identify different
clinical diagnoses in the EHRs (i.e., disease phenotyping [18]). To this end, we performed clustering analysis
using patients with the following eight complex disorders: T2D, MM, PD, Alzheimer’s disease (AD), Crohn’s
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disease (CD), breast cancer (BC), prostate cancer (PC), and attention deficit hyperactivity disorder (ADHD).
We used SNOMED–CT (Systematized nomenclature of medicine – clinical terms) [19] to find all patients
in the data warehouse diagnosed with these conditions; see Supplementary Table 2 and the “Multi-disease
clustering analysis” subsection in “Methods” for more details.
Evaluation was organized as a 2-fold cross-validation experiment to show model generalizability and to
assess replication of the stratification results. To this aim, we randomly split the dataset in half, obtaining
two independent cohorts of about 800, 000 patients that we used to train and test the models (and vice
versa). While we used all patients in each cohort for training, in the test sets we retained only the patients
diagnosed with one of the eight disorders under consideration, obtaining about 94, 000 test patients per fold
(see the “Dataset” subsection in “Methods” for more details).
Table 1 shows the results using hierarchical clustering for different ConvAE architectures (one, two, and
multikernel CNN layers) and baselines in terms of entropy and purity scores averaged over the 2-fold cross-
validation experiment. ConvAE performed significantly better than other models largely used in healthcare
for representation learning, including Deep Patient [20], for both entropy and purity scores (ps < 0.001, t-
tests comparisons with Bonferroni correction). The configuration with one CNN layer yielded the best overall
performance and the learned encodings produced clusters associated with the largest number of distinct
diseases (i.e, 6.50, based on purity score analysis). It is worth saying that, without a predictive theory
of clustering [21, 22], validation metrics frequently fail to correlate with clustering errors [23]. However,
such theoretic structure is not applicable in this context because the heterogeneity of the external complex
disorder classes do not provide a reliable probabilistic framework. For this reason, we used, rather than
estimation error analysis, transparent external metrics, such as entropy and purity scores, which evaluate
cluster composition and also account for possible subgroups of complex diseases [24].
Figure 2 visualizes the distribution of the different patient representations along with their disease cohort
labels obtained using UMAP (Uniform manifold approximation and projection for dimension reduction
[25]). ConvAE captures hidden patterns of overlapping phenotypes while still displaying identifiable groups
of patients with distinct disorders. Figure 3 shows the same patient distribution highlighting clustering
labels and purity percentage scores of each cluster dominating disease. These figures refer to only one of the
cross-validation splits; results for the second split are similar and are available in Supplementary Figures 1
and 2). ConvAE (with one CNN layer) also led to better clustering, visually, than all baselines. Patients with
ADHD were the most separated and detected with 80% purity by hierarchical clustering. Visible clusters
with > 50% purity were also identified for T2D, PC and PD. Comparing the encoding projections (Figure 2)
to the clustering visualization (Figure 3), we observe that patients whose disease is not correctly identified
by clusters tend to not clearly separate in this low-dimensional space. As an example, AD patients were
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randomly scattered in the plot and did not lead to distinguishable clusters. This might be due to factors
such as sex and age, intrinsic biases or noise, but it might also reflect a shared phenotypic characterization
that drives the learning process into displaying these patient EHR progressions closely together irrespective
of disease labels.
We then evaluated the use of ConvAE representations for patient stratification at scale and the identi-
fication of clinically relevant disease subtypes. We considered six diseases: T2D, PD, AD, MM, PC, and
BC. These are all age-related complex disorders with late onset (i.e., averaged increased prevalence after
60 years of age) [26, 27, 28, 29, 30, 31]. We decided to focus on these conditions to avoid, to some extent,
the confounding effect of age that could affect learning and the evaluation of different subtypes. Figure 4
shows results running hierarchical clustering on the ConvAE-based patient representations of each different
disease cohort. To determine the optimal number of clusters, we empirically selected the smallest number
of clusters that minimize the increase in explained variance (i.e., Elbow method). We were able to identify
different subtypes for each disease with no additional feature selection and using representations derived
from a domain-free cohort of patients. Supplementary Table 3 reports the number of patients in each cohort
and the number of subgroups identified. Similar results were obtained for the second split and are reported
in Supplementary Figure 3.
In the following sections, we present the clinical characterization of T2D, PD, and AD subgroups via
enrichment analysis of medical concept occurrences (see Supplementary Material for the characterization of
the other conditions). We compare T2D and PD results to related studies based on ad hoc cohorts [10, 11].
Conversely, there are no published EHR-based stratification studies for AD, MM, PC, and BC to use for
comparison. All subtypes were reviewed by a clinical expert to highlight meaningful descriptors and we used
multiple pairwise chi-squared tests to assess group differences. For each disease, we list sex and age statistics
of the cohort (between group comparisons are performed via multiple pairwise chi-squared tests and t-tests),
as well as the five most frequent diagnosis, medications, laboratory tests, and procedures, ordered according
to in-group and total frequencies, in Supplementary Tables 4-9. The results for the second split are reported
in Supplementary Tables 10-15.
Type 2 diabetes
Patients with T2D clustered into three different subgroups that relate to different stages of progression for
the disease (see Figure 4a and Supplementary Table 4 for details).
Subgroup I included 18, 325 patients and represents the mild symptom severity cohort, characterized
by common T2D symptoms (e.g., metabolic syndrome), which were treated with Metformin, an oral hypo-
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glycemic medication. Moreover, it also included patients exposed to lifestyle risk factors, such as Obesity
[6].
Subgroups II/III, which were composed by 22, 659 and 7, 704 patients, respectively, showed concomitant
conditions associated to T2D progression and worsening symptoms. Specifically, subgroup II clustered pa-
tients characterized by microvascular problems, such as diabetic nephropathy, neuropathy, and/or peripheral
artery disease. The significant presence of Creatinine and Urea nitrogen laboratory tests, which estimate
renal function, suggests monitoring of kidney diseases, which are often related to T2D [32]. The presence
of Pain in limb, combined with analgesic drugs (i.e., Paracetamol, Oxycodone), indicates the presence of
vascular lesions at the peripheral level, manifested as ischemic rest pain or ulceration. This was confirmed
by Peripheral vascular disease diagnoses which accounts for 50% of terms in the T2D cohort.
Subgroup III showed severe cardiovascular problems, identified by a significant presence of medical con-
cepts related to coronary artery diseases, e.g., Coronary atherosclerosis, Angina pectoris, which are serious
risk factors for heart failure. These subjects were often treated with antiplatelet therapy (i.e., Acetylsalicylic
acid, Clopidrogel) to prevent cardiovascular events (e.g., stroke) and were likely to receive invasive proce-
dures to treat severe arteriopathy. For instance, 30% of patients in subgroup III underwent Percutaneous
Transluminal Coronary Angioplasty, a procedure to open up blocked coronary arteries.
Our results confirm, in part, what was observed by Li et al. [10], which used topology analysis on an
ad hoc cohort of T2D patients and identified three distinct subgroups characterized by 1) microvascular
diabetic complications (i.e., diabetic nephropathy, diabetic retinopathy); 2) cancer of bronchus and lungs;
and 3) cardiovascular diseases and psychiatric disorders. In particular, we detected the same microvascular
and cardiovascular disease groups, which are consequences of T2D. In contrast, we were unable to detect
a subgroup significantly characterized by cancer, an epiphenomenon that can be caused by secondary im-
munodeficiency in patients with T2D [33, 34]. See Supplementary Material for further description and a
clustering comparison via Fowlkes-Mallows index.
Parkinson’s disease
Individuals diagnosed with PD divided into two groups (Figure 4b and Supplementary Table 5): one domi-
nated by motor symptoms (1, 368 patients) and another (1, 684 patients) characterized by non-motor/independent
features and longer course of disease.
Subgroup I is characterized as a tremor-dominant cohort (i.e., manifested by motor symptoms) because of
the significant presence of diagnosis such as Essential tremor, Anxiety state, and Dystonia. It is interesting
to note that motor clinical features likely led to a common misdiagnosis of essential tremor, which is an
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action tremor that typically involves the hands. Parkinsonian tremor, on the contrary, although can be
present during postural maneuvers and action, is much more severe at rest and decreases with purposeful
activities. However, when the tremor is severe, it is difficult to distinguish action tremor from resting
tremor, leading to the aforementioned misdiagnosis [35]. Moreover, anxiety states, emotional excitement,
and stressful situations can exacerbate the tremor, and lead to a delayed PD diagnosis. Brain MRI, usually
non-diagnostic in PD, was ordered for several patients in this subgroup (13%) suggesting its use for differential
diagnosis, e.g., to investigate the presence of chronic/vascular encephalopathy.
Subgroup II included non-motor and independent symptoms, such as Constipation and Fatigue. Patients
in subgroup II were significantly diagnosed with Coronary artery disease that is prevalent in older patients
(> 50 years old). Constipation and fatigue are among the most common non-motor problems related to
autonomic dysfunction, diminished activity level, and slowed intestinal transit time in PD [36, 37].
In their study about PD stratification with PPMI (Parkinson’s progression markers initiative) data,
Zhang et al. [11] identified three distinct subgroups of patients based on severity of both motor and non-
motor symptoms. In particular, one subgroup included patients with moderate functional decay in motor
ability and stable cognitive ability; a second subgroup presented with mild functional decay in both motor
and non-motor symptoms; and the third subgroup was characterized by rapid progression of both motor and
non-motor symptoms. EHRs do not quantitatively capture PD symptom severity, therefore our analyses
cannot replicate these findings. However, unlike Zhang et al., we can discriminate between specific motor
and non-motor symptoms and also suggest a longer, but not necessarily more severe, disease course for the
non-motor symptom subgroup.
Alzheimer’s disease
Patients with AD separated into three subgroups marked by AD onset, disease progression, and severity of
cognitive impairment (see Figure 4c and Supplementary Table 6).
Subgroup I is characterized by 399 patients with early-onset AD, i.e., patients whose dementia symptoms
have typically developed between the age of 30 and 60 years, and initial neurocognitive disorder. Early-onset
AD affects 5% of the individuals with AD in the US [38] and, because clinicians do not usually look for AD in
younger patients, the diagnostic process includes extensive evaluations of patient symptoms. In particular,
given that a certain AD diagnosis can only be provided post-mortem through brain examination, clinicians
first rule out other causes that can lead to early-onset dementia (i.e., differential diagnosis). We find evidence
of this practice in this subgroup, which includes postmenopausal women, identifiable by mean age greater
than 50, Osteoporosis diagnosis with calcium supplement therapy, and menopausal hormone treatment (i.e.,
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Estradiol). Patients in this group are also tested for infectious diseases (e.g., HIV, Syphilis, Hepatitis C,
Chlamydia/Gonorrhoea) that are possible causes of early-onset dementia [39], and screened via structural
neuroimaging, e.g., MRI/PET brain. As cognitive dysfunctions that may be mistaken for dementia can also
be caused by depression and other psychiatric conditions, the presence of Psychiatric service/procedure sug-
gests psychiatric evaluations to exclude depressive pseudodementia. After the differential diagnosis process
and the exclusion of other possible causes, eventually these patients received a diagnosis of AD.
Subgroup II includes 1, 170 patients with late-onset AD, mild neuropsychiatric symptoms and cerebrovas-
cular disease. Here, the absence of behavioral disturbances in 39% of patients, and their high average age
(M = 84.96, sd = 9.61) suggest a late AD onset, with a progression characterized by a slower rate of
cognitive ability decline [40]. Moreover, the presence of Acetylsalicylic acid, an antiplatelet medication, and
Intracranial hemorrage diagnosis indicates the co-occurrence of cerebrovascular disease, which affects blood
vessels and blood supply to the brain. Cerebrovascular diseases are common in aging, and can often be
associated with AD [41]. In this regard, Head CT may have been performed to prevent or identify structural
abnormalities related to cerebrovascular disease.
Subgroup III is characterized by 1, 632 individuals with typical onset and mild-to-moderate dementia
symptoms. A cohort of 409 patients was treated with Donepezil, a cholinesterase inhibitor, that is a primary
treatment for cognitive symptoms and it is usually administered to patients with mild-to-moderate AD,
producing small improvement in cognition, neuropsychiatric symptoms, and activities of daily living [42].
Patients in this subgroup also showed both dementia with and without behavioral disturbances.
Discussion
This study proposes a computational framework to disentangle the heterogeneity of complex disorders in
large-scale EHRs through the identification of data-driven clinical patterns with machine learning. Specif-
ically, we developed and validated an unsupervised architecture based on deep learning (i.e., ConvAE) to
infer informative vector-based representations of millions of patients from a large and diverse hospital set-
ting, which facilitates the identification of disease subgroups that can be leveraged to personalize medicine.
These representations aim to be domain-free (i.e., not related to any specific task since learned over a large
multi-domain dataset) and enable patient stratification at scale. Results from our experiments show that
ConvAE significantly outperformed several baselines on clustering patients with different complex conditions
and led to the identification of different clinically meaningfully disease subtypes.
Results identified disease progression, symptom severity, and comorbidities as contributing the most to
the EHR-based clinical phenotypic variability of complex disorders. In particular, T2D patients divided
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into three subgroups according to comorbidities (i.e., cardiovascular and microvascular problems) and symp-
tom severity (i.e., newly diagnosed with milder symptoms). Individuals with PD showed different disease
duration and symptoms (i.e., motor, non-motor). AD profiles distinguished early- and late-onset groups
and separate patients with mild neuropsychiatric symptoms and cerebrovascular disease from patients with
mild-to-moderate dementia. Patients with MM were characterized by different comorbidities (e.g., amyloi-
dosis, pulmonary diseases) that manifest alongside precise typical signs of MM. Patients with PC and BC
separated according to disease progression. These findings showed that the features learned by ConvAE
describe patients in a way that is general and conducive to identifying meaningful insights into different
clinical domains. In particular, this work aims to contribute to the next generation of clinical systems that
can 1) scale to include many millions of patient records and 2) use a single, distributed patient representation
to effectively support clinicians in their daily activities, rather than multiple systems working with different
patient representations derived for different tasks [20].
To this aim, enabling efficient data-driven patient stratification analyses to identify disease subgroups
is an important aspect to unlock personalized healthcare. Ideally, when new patients enter the medical
system, their health status progression can be tied to a specific subgroup, thereby informing the treating
clinician of personalized prognosis and possible effective treatment strategies, or counseling in cases where
a certain diagnosis is difficult and a more thorough examination is required (e.g, specific genetic or lab
tests). Moreover, the clinical characteristics of the different subtypes can potentially lead to intuitions for
novel discoveries, such as comorbidities, side-effects or repositioned drugs, which can be further investigated
analysing the patient clinical trajectories.
Previous studies mostly focused on a specific disease using ad hoc cohorts of patients and features [8, 9, 10,
11, 43, 44]. While these studies obtained relevant clinically meaningful results, the computational framework
is hard to replicate for different diseases and it is tied to the specific study and to the specific data. Deep
learning has extensively been used to model EHRs for medical analysis [15, 16], including clinical prediction,
such as disease onset, mortality, and readmission [45, 46, 47], and disease phenotyping [20, 48]. Because deep
learning methods have not yet been leveraged for disease subtyping at scale, ConvAE aims to fill this gap and
to provide an architecture that can improve unsupervised EHR pre-processing to favor patient stratification
and unveil clinically meaningful and actionable insights. Additionally, unlike previous representation learning
methods which did not consider the temporality of EHRs [20, 48], ConvAE uses CNNs in combination with
embeddings to specifically capture some of the longitudinal aspects of patient clinical status, leading to more
robust representations. CNNs were already used to model EHRs for specific predictive analysis, as part
of supervised architectures [49, 50]. Differently, we trained CNNs in an unsupervised framework based on
autoencoders to learn general-purpose patient representations. While these representations were used to
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leverage disease subtype discovery, they can also be fine-tuned and applied to specific supervised tasks, such
as disease phenotyping and prediction.
There are several limitations to our study. First, we acknowledge that the lack of any discernible pattern
in the multi-disease clustering analysis can also be due to noise and biases in the data, which might affect both
learned representations and clustering. In particular, processing EHRs with minimum data engineering, on
the one hand, preserves all the available information and, to some extent, prevents systematic biases. On the
other, it adds hospital-specific biases intrinsic to the EHR structure and noise due to data being redundant
and too generic. Improving EHR pre-processing by, e.g., better modeling clinical notes and/or improving
feature filtering, should help reduce noise and improve performances. Second, we identified patients related
to complex disorders using SNOMED–CT codes and this likely led to the inclusion of many false positives
that affected the learning algorithms [51]. The use of phenotyping algorithms based on manual rules, e.g.,
PheKB [52], or semi-automated approaches, e.g. [53, 54]), should help identify better cohorts of patients
and, consequently, better disease subtypes. Another limitation comes from the choice, among all possibilities,
of the specific complex disorders. This allowed us to test the approach on heterogeneous conditions that
affect different biological mechanisms, showing the efficacy of the proposed framework in generalizing to
various clinical domains. Nevertheless, the approach should be further evaluated with other typologies
of conditions as well, such as multiple sclerosis, autoimmune diseases, and psychiatric disorders. Lastly,
we identified relevant concepts in the patient subgroups by simply evaluating their frequency. Adding a
semantic modeling component based on, e.g., topic modeling [55] or word embeddings [56], might lead to
more clinically meaningful patterns.
Future works will attempt to address these limitations and to further improve and replicate the architec-
ture. First, we plan to enable multi-level clustering in order to stratify patients within the subtypes. This
should lead to more granular patient stratification and thus, to patterns on a more individual-level. Sec-
ond, we plan to verify ConvAE generalizability by replicating the study on EHRs from different healthcare
institutions. Third, we will evaluate the use of disease subtypes as labels for training supervised models
that can predict stratified patient risk scores. This, beside further validating the relevance of the results,
will also provide an initial and intuitive framework to apply the results of patient stratification to clinical
practice. To this aim, we plan to first assess treatment safety and efficacy between subtypes of a specific
disease. Finally, to develop more comprehensive disease characterizations, we will include other modalities
of data, e.g., genetics, into this framework, which will hopefully refine clustering and reveal new etiologies.
Multi-modal stratified disease cohorts promise to facilitate better predictive capabilities for future outcomes
by modeling how molecular mechanisms interact with clinical states.
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Methods
The framework to derive patient representations that enable stratification analysis at scale is based on 3
steps: 1) data pre-processing; 2) unsupervised representation learning (i.e., ConvAE); and 3) clustering
analysis of disease-specific cohorts (see Figure 1a). In this section, we report details of this framework as
well as the description of the evaluation design.
Dataset
We used de-identified EHRs from the Mount Sinai Health System data warehouse; the study was approved
by IRB-19-02369 in accordance with HIPAA guidelines. Mount Sinai Health System is a large and diverse
urban hospital located in New York, NY, which generates a high volume of structured, semi-structured and
unstructured data from inpatient, outpatient, and emergency room visits. Patients in the system can have
up to 12 years of follow-up data unless they are transferred or move their residence away from the hospital
system. We accessed a de-identified dataset containing approximately 4.2 million patients, spanning the
years from 1980 to 2016.
For each patient, we aggregated general demographic details (i.e., age, sex, and race) and clinical de-
scriptors. We included ICD-9 diagnosis codes, medications normalized to RxNorm, CPT-4 procedure codes,
vital signs, and lab tests normalized to LOINC. ICD-10 codes were mapped-back to the corresponding ICD-9
versions. We pre-processed clinical notes using a tool based on the Open Biomedical Annotator that extracts
clinical concepts from the free-text [57, 58]. The vocabulary V was composed by 57, 464 clinical concepts.
We retained all patients with at least two concepts, resulting in a collection of 1, 608, 741 different patients,
with an average of 88.9 records per patient. In particular, the cohort included 900, 932 females, 691, 321
males, and 16, 488 not declared; the mean age of the population as of 2016 was 48.29 years (sd = 23.79).
Patients were randomly partitioned in half for 2-fold cross-validation to assess model generalizability and
replicability of the results. In each train set, we retained 30, 000 random patients for tuning the model
hyperparameters. Train and test pre-processed sets’ details are reported in Supplementary Table 1.
Data pre-processing
Every patient in the dataset is represented as a longitudinal sequence sp of length M of aggregated temporally-
ordered medical concepts, i.e., sp = (w1, w2, . . . , wM ), where each wi is a medical concept from the vocab-
ulary V . Pre-processing includes: 1) filtering the least and most frequent concepts; 2) dropping redundant
concepts within fixed time frames; 3) splitting long sequences of records to include the complete patient
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history while leveraging the CNN framework, which requires fixed-size inputs.
We consider all the EHRs as a document D and each patient sequence sp as a sentence. For each
concept w in V we first compute the probability of having w in D. We then multiply this by the sum of
the probabilities to find w in a sentence sp for all sentences. In particular, let P be the set of all patients,
∀w ∈ V , the filtering score is defined as:
P(w ∈ D)
∑
p∈P
P(w ∈ sp) = #{s ∈ D; w ∈ s}|D|
∑
p∈P
#{wi ∈ sp; wi = w}
|sp| , (1)
where |D| is the total number of sentences and |sp| is the length of a patient sequence. The filtering
score combines document frequency, i.e., number of patients with at least one occurrence of w, and term
frequency, i.e., total number of occurrences of w in a patient sequence. We then drop all concepts with
filtering scores outside certain cut-off values to reduce the amount of noise (i.e., not informative concepts
that occur multiple times in few patients, or too general concepts that occur in many patients).
A patient may have multiple encounters in their health records that span consecutive days and might
include repeated concepts that are often artifacts of the EHR system, rather than new clinical entries. To
reduce this bias, we drop all duplicate medical concepts from the patient records within overlapping time
intervals of T days. Within the same time window, we also randomly shuffle the medical concepts, given
that events within the same encounter are generally randomly recorded [59, 54]. Lastly, we eliminate all
patients with less than 3 concepts in their records.
Patient sequences are then chopped into subsequences of fixed length L that are used to train the ConvAE
model. Each patient sequence is thus defined as:
sp = [(w1, . . . , wL), (wL+1, . . . , w2L), . . . ],
and subsequences shorter than L are padded with 0 up to length L. For the sake of clarity, in the following
section we present the architecture as applied to a general subsequence s = (w1, . . . , wL).
The ConvAE architecture
ConvAE is a representation learning model that transforms patient EHR subsequences into low-dimensional,
dense vectors. The architecture consists of three stacked modules (see Figure 1b). This study proposes
to use in combination embedding, CNNs, and autoencoders to process EHRs and to derive unsupervised
vector-based patient representations that can be used for clinical inference and medical analysis.
Given s, the architecture first assigns each medical concept w to an N -dimensional embedding vector
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vw to capture the semantic relationships between medical concepts. Specifically, a patient subsequence is
represented as an (L×N) matrix E = (vw1 , vw2 , . . . , vwL)T , where L is the subsequence length, and N is
the embedding dimension. This structure also retains temporal information because the rows of matrix E
are temporally ordered according to patient visits.
The architecture is then composed by CNNs, which extract local temporal patterns, and AEs, which
learn the embedded representations for each patient subsequence. The CNN applies temporal filters to each
embedding matrix. CNN filters applied to EHRs usually perform a one-side convolution operation across
time via filter sliding. A filter can be defined as k ∈ Rh×N , where h is the variable window size and N is
the embedding dimension [60, 61]. Our approach differs in that it processes embedding matrices as they
were RGB images carrying a third “depth” dimension. With this approach, we enable the model filters to
learn independent weights for each encoding dimension, thus activating for the most salient features in each
dimension of the embedding space. Therefore, we reshape the (L×N) embedding matrix into E˜ ∈ R1×L×N
and we consider the embedding dimensions as channels. We then apply f filters k ∈ R1×h×N to the padded
input to keep the same output dimension and learn features that may grasp sequence characteristics. In
particular, for each filter j, we obtain:
(R)j = ReLU(
N−1∑
i=0
ki ? e˜i + bj), j = 1, . . . , f, (2)
where: R ∈ R1×L×f is the output matrix; ki is the h-dimensional weight matrix at depth i; e˜i ∈ R1×L is
the i-th embedding dimension of the input matrix; b is the bias vector; and (?) is the convolution function.
We used Rectified Linear Unit (ReLU) as the activation function and max pooling. The output is then
reshaped into a concatenated vector of dimension L · f . This configuration learns different weights for each
embedding dimension to highlight relevant interdependencies of medical concepts, and tune representations
of patient histories to identify the most relevant characteristics of their semantic space.
We then use fully dense layers of autoencoders to derive embedded patient representations that estimate
the given input subsequences. Specifically, we extract the hidden representation y, a H-dimensional vector,
as the encoded representation of each patient subsequence. Each patient sequence sp is then transformed into
a sequence of encodings sh that can be post-modeled to obtain a unique vector-based patient representation.
Here we simply component-wise average all the subsequence representations.
To train ConvAE, we set up a multi-class classification task that reconstructs each initial input one-hot
subsequence of medical terms, from their encoded representations. Given a subsequence of medical concepts
s, the ConvAE is trained by minimizing the Cross Entropy (CE) loss:
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CE(Softmax(O), s) = − 1
L
L∑
j=1
log(Softmax(Oj)wj ),
where O is the output of ConvAE reshaped into a matrix of dimension |V | ×L, wj is the j-th element of
sequence s that correspond to a term indexed in V and:
Softmax(Oj)i =
expOji∑|V |
i=1 expO
j
i
i = 1, ..., |V |. (3)
Since the objective function consists of only self-reconstruction errors, the model can be trained without
any supervised training samples.
Clustering analysis for patient stratification
ConvAE-based representations can be used to stratify patients from any preselected cohort without needing
additional feature engineering or manual adjustments. To this aim, patients with a specific disease are
selected using, e.g., ICD codes, SNOMED–CT diagnosis, or phenotyping algorithms (e.g., [51, 53, 54]), and
clustering is applied to the corresponding representations to identify disease subgroups. Here, specifically,
we use SNOMED–CT diagnosis to preselect the disease cohorts and hierarchical clustering with Ward’s
method and Euclidean distance to derive disease subgroups. We identify the number of subclusters that
best disentangles heterogeneity on the disease dataset using the Elbow Method, which empirically selects
the smallest number of clusters that minimize the increase in explained variance.
A systematic analysis of the patients in each subgroup can then automatically identify the medical
concepts that significantly and uniquely define each disease subtype. In this work, we rank all the codes
by their frequency in the patient sequences. In particular, we compute the percentages of patients whose
sequence includes a specific concept both with respect to a subcluster (i.e., in-group frequency) and to
the complete disease cohort (i.e., total frequency). Ranking maximizes, first, the in-group percentage, and
second, the total percentage. We then analyze the most frequent concepts and we use a pairwise chi-squared
test to determine whether the distributions of present/absent concepts with respect to the detected subgroups
are significantly different [11].
Implementation details
All model hyperparameters were empirically tuned to minimize the network reconstruction error, while
balancing training efficiency and computation time. We tested a large amount of configurations (e.g., time
interval T equal to {15, 30}; patient subsequence length L equal to {32, 64}; embedding dimension N
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spanning {100, 128, 200}). For brevity, we report only the final setting used in the patient stratification
experiments. All modules were implemented in Python 3.5.2, using scikit-learn and pytorch as machine
learning libraries [62, 63]. Computations were run on a server with an Nvidia Titan V GPU.
We used equation (1) to discard terms with a filtering score less than 10−6, i.e., document frequency
ranging from 1 to 10. Examples of discarded concepts are clotrimazole, an antifungal medication, and
torsemide, a medication to reduce extra fluid in the body. We decided to retain all the very frequent
concepts as most of them seemed clinically informative (e.g., vital signs). Patients with less than 3 medical
concepts were then discarded. In total, 24, 665 medical terms were filtered out, decreasing the vocabulary
size to 32, 799.
We divided each patient history in consecutive, half-overlapped temporal windows of T = 15 days, shuffled
unique medical concepts and dropped redundant terms. Patient sequences were then split in subsequences
of length L = 32 concepts, obtaining about ∼ 3M subsequences of medical concepts for training. This value
was chosen to enable efficient training of the autoencoder with GPUs.
We initialized medical concept embeddings using word2vec with the skip-gram model [56]. We considered
all the subsequences in the training set as sentences and medical concepts as words [54, 59]. We obtained
100-dimensional embeddings for 31, 659 medical concepts of the vocabulary. The remaining concepts were
initialized randomly; the subsequence padding was initialized as the null vector (i.e., at 0). These embedding
vectors were then used as input for the ConvAE module and were further refined during the model training.
The CNN module used 50 filters with kernel size equal to 5 and ReLU activation function. The autoen-
coder was composed by 4 hidden layers with 200, 100, 200 and |V | × 32 hidden nodes, respectively, where
|V | is the vocabulary size. We used ReLU activation in the first three layers and Softplus activation in
the final layer to obtain continuous output. We applied dropout with p = 0.5 in the first two layers for
regularization. The model was trained using cross entropy loss with the Adam optimizer (learning rate =
10−5 and weight decay = 10−5) [64] for 5 epochs on all training data and batch size of 128. The size of the
patient representations was equal to 100.
We evaluated different CNN configurations composed by 1-layer (i.e., “ConvAE 1-layer CNN”), 2-layers
(i.e., “ConvAE 2-layer CNN”), and one multikernel layer (i.e., “ConvAE multikernel CNN”). All hyperpa-
rameters were the same, except the number of filters in the second CNN of the 2-layer configuration that
was set to 25. Multikernel CNN performs parallel training of distinct CNNs with different kernel sizes, and
concatenates the final outputs. We used kernel dimensions equal to 3, 5, and 7.
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Baselines
We compared ConvAE with the following representation learning algorithms: “RawCount”, “SVD-RawCount”,
“SVD-TFIDF”, and “Deep Patient”. All baselines derived vector-based patient encodings of size 100.
RawCount is a sparse representation where each patient is encoded into a count vector that has the
length of the vocabulary. More specifically, each individual health history sp is represented as an integer
vector x ∈ Z|V |, where each element is the frequency of the corresponding clinical concept in the patient
longitudinal history , i.e., xi = #{wi; wi ∈ sp}.
SVD-RawCount applies truncated singular value decomposition (SVD) to the RawCount matrix to com-
pute the largest singular values of the raw count encodings, which define the dense, lower-dimensional
representations.
SVD-TFIDF transforms the raw count encodings using the term frequency–inverse document frequency
(TFIDF) weighting schema and applies truncated SVD to the resulting matrix. We considered the patient
EHR sequences as documents, the entire dataset as corpus and we derived TFIDF scores for all medical
concepts. Each patient is then represented as a vector of length |V |, with the corresponding TFIDF weight
for each concept, and the matrix obtained is reduced via truncated SVD.
Deep Patient transforms the raw count matrix using a stack of denoising autoencoders as proposed by
Miotto et al. [20]. We used the implementation details presented in the paper, with batch size equal to 32,
corruption noise equal to 5%, and 5 training epochs.
Multi-disease clustering analysis
We evaluated all the representation learning approaches in a clustering task to determine how they were
able to disentangle patients with different conditions. We chose eight complex disorders: type 2 diabetes
(T2D), multiple myeloma (MM), Parkinson’s disease (PD), Alzheimer’s disease (AD), Crohn’s disease (CD),
prostate cancer (PC), breast cancer (BC) and attention deficit hyperactivity disorder (ADHD). We retrieved
all the corresponding patients in the test sets using SNOMED–CT codes after verifying that at least one
correspondent ICD-9 code was present in a patient EHRs. In particular, we looked for Type 2 diabetes
mellitus (250.00) for T2D; Multiple myeloma without mention of having achieved remission (203.00) for MM;
Paralysis agitans (332.0) for PD; Alzheimer’s disease (331.0) for AD; Regional enteritis of unspecified site
(555.9) for CD; Malignant neoplasm of prostate (185) for PC; Malignant neoplasm of female breast (174.9)
for BC; and Attention deficit disorder with hyperactivity (314.01) for ADHD. We discarded all patients with
comorbidities within the selected diseases to facilitate the clustering interpretation. We then performed
hierarchical clustering with k = 8 clusters (i.e., same as the different diseases) for all the representations
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to evaluate if patients with the same condition were grouping together. The final test sets were composed
by about 94, 000 patients per fold but were unbalanced, with disease cohorts ranging from about 1, 900 to
50, 000 patients (see Supplementary Table 2). To use balanced datasets and improve the efficacy of the
experiment, we sub-sampled 5, 000 random patients for the highly populated diseases, and we iterated this
subsampling process 100 times, obtaining 100 different clustering per test set.
We used entropy and purity scores averaged across the 100 experiments of each fold to measure to what
extent the clusters matched the different diseases. In particular, for each cluster j, we define the probability
that a patient in j has disease i as:
pij =
mij
mj
, (4)
where mj is the number of patients in cluster j and mij is the number of patients in cluster j with a
diagnosis of disease i. Entropy for each cluster is defined as:
Ej = −
∑
i
pij log2 pij , (5)
and conditional entropy H(disease|cluster) is then computed as:
H(disease|cluster) =
∑
j
mj
m
Ej ,
where m is the total number of elements in the complex disease dataset.
Purity identifies the most represented disease in each cluster. For a cluster j, purity Pj is defined as
Pj = maxi pij , where pij is computed as before. The overall purity score is then the weighted average of
Pj for each cluster j. The perfect clustering obtains averaged entropy and purity scores equal to 0 and 1,
respectively.
Disease subtyping analysis
We evaluated the usability of ConvAE representations to discover disease subtypes for different and diverse
conditions (i.e., patient stratification at scale). In particular, we selected a cohort of patients with T2D, PD,
AD, MM, PC, and BC and ran hierarchical clustering on the ConvAE-based patient representations. These
are all age-related complex disorders with late onset (i.e., increased prevalence after 60 years of age [26,
27, 28, 29, 30, 31]). We focused only on these conditions to attempt reducing confounding age effects that
could affect the analysis of the subtypes (as it could happen on CD and ADHD cohorts, where a common
onset age is less defined). To reduce noise in the sequence encodings, we averaged all patient subsequence
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representations from the first diagnosis forward, and we dropped sequences shorter than 3 concepts. We
ranged the number of clusters from 2 to 15 and we used the Elbow Method to empirically select the smallest
number of clusters that minimize the increase in explained variance. We then performed a qualitative analysis
of each subtype, similarly to Zhang et al. [11], to identify which medical concepts characterized the specific
group of patients. We further verified the various subgroups in the medical literature and with the support
of a practicing clinician.
Data availability
The data used for this study are available from the Mount Sinai Health System (NYC), but restrictions
apply to the availability of these data, which were used under license for the current study, and so are not
publicly available. Data are however available from the authors upon reasonable request and with permission
of Mount Sinai Health System.
Code availability
Code is available at: https://github.com/landiisotta/convae_architecture.
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Entropy1 Purity1 Disease Number2
ConvAE 1-layer CNN 2.61 (0.04, [2.58, 2.67])∗∗∗ 0.31 (0.02, [0.31, 0.35])∗∗∗ 6.50 (0.62)∗∗∗
ConvAE 2-layer CNN 2.75 (0.02, [2.74, 2.78]) 0.26 (0.01, [0.26, 0.29]) 5.93 (0.50)
ConvAE multikernel CNN 2.66 (0.03, [2.64, 2.70]) 0.30 (0.02, [0.29, 0.33]) 5.94 (0.47)
RawCount 2.90 (0.02, [2.88, 2.92]) 0.18 (0.01, [0.18, 0.20]) 4.76 (0.70)
SVD-RawCount 2.90 (0.01, [2.90, 2.92]) 0.19 (0.01, [0.18, 0.20]) 5.13 (0.79)
SVD-TFIDF 2.85 (0.02, [2.84, 2.87]) 0.21 (0.01, [0.21, 0.23]) 5.83 (0.76)
Deep Patient 2.81 (0.02, [2.80, 2.84]) 0.24 (0.01, [0.23, 0.25]) 5.96 (0.74)
1 Mean (sd, CI); 2 Mean (standard deviation); ∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001;
CNN = Convolutional Neural Network; SVD = Singular Value Decomposition;
TFIDF = Term Frequency - Inverse Document Frequency
Table 1: Multi-disease clustering performances of ConvAE configurations and baselines. The scores reported
are averaged over a 2-fold cross-validation experiment. ConvAE 1-layer CNN significantly outperforms all
other configurations and baselines on all measures. Multiple pairwise t-tests with Bonferroni correction are
used to compare performances.
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Figure 1: Patient stratification framework and ConvAE architecture. (a) Framework enabling patient strat-
ification analysis from deep unsupervised EHR representations; (b) Details of the ConvAE representation
learning architecture.
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AD = Alzheimer’s disease; ADHD = Attention deficit hyperactivity disorder; BC = Breast cancer; CD = Crohn’s disease;
MM = Multiple myeloma; PC = Prostate cancer; PD = Parkinson’s disease; T2D = Type 2 diabetes
Figure 2: Uniform manifold approximation and projection (UMAP) encoding visualization. (a) ConvAE
1-layer CNN; (b) SVD-RawCount; (c) SVD-TFIDF; (d) Deep Patient. AD = Alzheimer’s disease; ADHD
= Attention deficit hyperactivity disorder; BC = Breast cancer; CD = Crohn’s disease; MM = Multiple
myeloma; PC = Prostate cancer; PD = Parkinson’s disease; T2D = Type 2 diabetes.
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AD = Alzheimer’s disease; ADHD = Attention deficit hyperactivity disorder; BC = Breast cancer; CD = Crohn’s disease;
MM = Multiple myeloma; PC = Prostate cancer; PD = Parkinson’s disease; T2D = Type 2 diabetes
Figure 3: Uniform manifold approximation and projection (UMAP) clustering visualization. (a) ConvAE
1-layer CNN; (b) SVD-RawCount; (c) SVD-TFIDF; (d) Deep Patient. AD = Alzheimer’s disease; ADHD
= Attention deficit hyperactivity disorder; BC = Breast cancer; CD = Crohn’s disease; MM = Multiple
myeloma; PC = Prostate cancer; PD = Parkinson’s disease; T2D = Type 2 diabetes.
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Figure 4: Complex disorder subgroups. A subsample of 5, 000 patients with T2D is displayed in Figure (a).
Figures (b), (c), (d), (e), (f) display patient subtypes for Parkinson’s and Alzheimer’s disease, multiple
myeloma, prostate and breast cancer cohorts, respectively.
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Supplementary Material
Clustering comparison for the type 2 diabetes analysis
Li et al. [1] used a similar cohort of EHRs as in this study to stratify patients with type 2 diabetes (T2D).
Of the 2, 472 patients from their paper, we identified 1, 050 of them in our test sets. To compare the results,
we evaluated the similarity of the clusters we obtained to those found by Li et al. via the Fowlkes-Mallows
index (FMI), which is an external validation similarity measure of two cluster analyses [2, 3]. FMI scores
range from 0 to 1, where 1 represents identical clustering and 0 purely independent label assignments. We
obtained FMI = 0.40, which suggests that only a portion of patients in groups from Li et al. [1] are identified
by our approach as sharing the same characteristics. This may entail that associated clinical phenotypes
overlap to a greater extent than hypothesized by Li et al., which may have been overlooked because they
collected shorter EHR sequences (i.e., 60 day intervals) and used a manually derived subset of features.
Disease subtyping
Multiple myeloma We identified five subgroups for multiple myeloma (MM) (see Figure 4d and Sup-
plementary Table 7). In particular, subgroup I is characterized by pulmonary manifestations; subgroup II
shows bone-related signs of MM; subgroup III includes signs of gastrointestinal problems; subgroup IV is
defined by kidney problems; and subgroup V shows signs of peripheral neuropathy.
Pulmunary manifestations in subgroup I include Pleura effusion, a rare pulmonary manifestation of
amyloidosis [4] that is a comorbidity of MM found in 10− 15% of patients (i.e., superimposed amyloidosis).
Subgroup I is also characterized by patients with amyloidosis and proteinuria (i.e., excess of proteins in
urine) because of the large frequency of Urea nitrogen blood test.
Disorders of bone and cartilage largely characterizes patients in subgroup II, which can be identified with
bone-related signs of MM.
Subgroups III and V include patients who received chemotherapy and/or anti-cancer medications. In
particular, we often found Bortezomib in combination with Dexamethasone in both subgroups. Bortezomib,
for example, is administered to 47% of patients from subgroup III and to 26% of patients in group V. It can
be used: 1) for patients ineligible for hematopoietic cell transplantation (HCT); 2) as a maintenance therapy;
or 3) in conjunction with HCT for newly-diagnosed patients [5]. Given the characterization of subgroups
III and V we expect gastrointestinal problems in subgroup III and Inflammatory/toxic neuropathy diagnosis
in subgroup V to indicate different side effects from anti-cancer medications. Peripheral nerve damage is
also one of the most significant non-hematologic toxicities of Bortezomib [6]. Although unlikely, neurologic
complications can also be caused by MM. Such neurologic complications can be due to spinal cord compression
from an extramedullary plasmacytoma, or by peripheral neuropathy, which is rare and usually caused by
superimposed amyloidosis [7]. The Counseling concept in subgroup V likely denotes an encounter to treat
severe pain linked to neurologic diseases or psychological support.
Creatinine, Urea nitrogen, and Urinalysis testing indicate renal function estimate for patients in sub-
group IV. Moreover, 9% of patients report Nephritis and nephropathy and Chronic kidney disease diagnosis,
reinforcing the association of subgroup IV to kidney conditions.
Prostate cancer We find 2 subgroups of patients with prostate cancer (PC) related to diverging disease
courses (see Figure 4e and Supplementary Table 8).
Clinical manifestation of PC is heterogeneous and may range from asymptomatic screen, microscopic, well
differentiated tumor, that may never become clinically relevant; to clinically symptomatic aggressive cancer
that causes metastases, morbidity, and death. Treatment approaches for PC include: active surveillance,
radical prostatectomy, or radiation therapy (RT) for patients with low-risk PC; prostatectomy or RT in
1
combination with Androgen Deprivation Therapy (ADT) for patients with higher-risk, but localized PC; RT
and ADT for patients with clinical evidence of lymph node involvement.
Patients in subgroup I report Personal history of PC and Ondansetron medication to prevent RT side
effects. This suggests that this group includes patients with recurrent prostate cancer that have either
received prostatectomy in the past, and hence RT and ADT is required, or, have already received RT and
thus require a radical approach. Anastomosis and Pelvic lymphadenectomy concepts, which are related to
post-prostatectomy procedures and are frequent in these patients, support this description.
Clinical manifestations of PC are usually absent at the time of diagnosis, and over 90% of patients are
diagnosed via specific screening (e.g., use of prostate-specific antigen (PSA) or digital rectal examination).
Patients in subgroup II show frequent signs of effective PSA screening, indicating probable localized and
asymptomatic PC. Diagnosis of Nocturia, Impotence of organic origin, Urinary frequency, and treatments
for male sexual dysfunctions, i.e., Tadalafil, Sildenafil, are all signs of side effects from PC treatments [8].
Among them, at least 22% likely received a prostatectomy (Surgery).
Differently from the second subgroup, patients in the first subgroup do not have PSA among top-ranked
concepts. This suggests that subgroup I includes patients that already received prostatectomy, which makes
PSA screening less common. Patients in subgroup I appear to have been in the healthcare system for longer
and also to have been diagnosed with PC earlier (i.e., similar median age to subgroup II, but absent PSA
screening).
Breast cancer Stratification of breast cancer (BC) patients lead to two different subgroups (see Figure
4f and Supplementary Table 9). Subgroup I is linked to advanced stages of BC. Patients in subgroup II,
instead, are younger and present a high number of screening-related medical concepts (e.g., Mammography
screening). In addition, concepts like Abnormal mammogram and Carcinoma in situ of breast suggest an
early-stage diagnosis.
In subgroup I, 23% of patients reports Unlisted chemotherapy, with Surgery performed on 44% of them.
This suggests that these patients may have a more advanced disease, as also evidenced by the lack of
screening terms. As a result, they typically undergo chemotherapy treatment, which is more common in
advanced stages of BC, whereas primary surgery (lumpectomy, mastectomy), with or without radiation
therapy, is preferred for early-stage cancer. This group also includes patients that have already received
surgical treatments (33% having received a partial mastectomy) and thus can either be disease free or have
relapsed. The presence of Secondary malignant neoplasm also suggests that subgroup I includes patients
with metastatic BC.
It would be important to better characterize what the general concepts Unlisted chemotherapy and
Antineoplastic chemotherapy specifically refer to in terms of more specific treatments (e.g., hormonal drugs,
immunotherapy) to better understand the clinical characteristics of the different subgroups. Moreover,
because different molecular subtypes of BC have been identified based on gene expression profiling [9],
including hormonal profiles of patients (not available for this study) might improve the stratification results.
Replication of disease subtyping
In the following, we present the patient stratification results obtained with the second split. As highlighted
in Supplementary Figure 3, we found slightly different subgroups only for PC and MM (when compared with
the results of the first split).
MM encodings detect 4 instead of 5 subgroups. We found two subgroups showing kidney-related problems,
one subgroup reporting signs of chemotherapy treatment side effects (i.e., Inflammatory/toxic neuropathy)
and one subgroup identified by signs of possible superimposed amyloidosis, i.e., Disease of salivary glands.
Patients with PC split into three subgroups, where subgroups II and III appears to be a further refinement
of subgroup II identified in the first split. In particular, subgroup III includes significantly younger subjects
compared to subgroup II. The presence of Personal history of PC suggests that subgroups II includes patients
2
with relapsing PC. This subgroup is of particular importance for the investigation of treatment effectiveness.
The analysis for the other diseases led to very similar results to those obtained with the first split. In
particular, for T2D we identified three subgroups: a group with signs of metabolic syndrome and T2D risk
factors, a group with microvascular problems, and a third group showing signs of cardiovascular disorders.
Patients with PD separates into two subgroups, with motor and non-motor symptoms, respectively, as
previously found. AD and BC are again characterized by three and two subgroups, respectively, with the
same clinical profiles previously presented.
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Split 1 Split 2
Train Test Train Test
Patients 741, 177 751, 979 740, 922 751, 900
Median sequence length 41 40 41 40
Subsequences 3, 636, 014 3, 656, 238 3, 644, 596 3, 647, 426
Mean N of subseq per patient (sd) 4.91 (12.13) 4.86 (12.06) 4.92 (12.14) 4.85 (12.06)
Vocabulary size 32, 799 32, 156 32, 875 32, 210
Supplementary Table 1: Train and test set characteristics.
Complex disorder Test set 1 Test set 2
Type 2 diabetes 50, 253 50, 327
Parkinson’s disease 3, 124 3, 150
Alzheimer’s disease 3, 374 3, 311
Multiple myeloma 1, 947 1, 935
Prostate cancer 14, 401 14, 508
Breast cancer 8, 330 8, 156
Crohn’s disease 6, 668 6, 741
ADHD 6, 510 6, 312
ADHD = Attention deficit hyperactivity disorder
Supplementary Table 2: Number of subjects in the complex disorder cohorts.
Test set 1 Test set 2
Numerosity N clusters Numerosity N clusters
T2D 48, 688 3 48, 759 3
PD 3, 052 2 3, 071 2
AD 3, 201 3 3, 150 3
MM 1, 884 5 1, 883 4
PC 8, 522 2 8, 645 3
BC 7, 964 2 7, 838 2
T2D = Type 2 diabetes; PD = Parkinson’s disease; AD = Alzheimer’s disease;
MM = Multiple myeloma; PC = Prostate cancer; BC = Breast cancer
Supplementary Table 3: Complex disorder cohorts and number of subclusters identified via patient stratifi-
cation.
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Parkinson’s disease
Subgroup I Subgroup II
(N=1, 368) (N=1, 684)
Female/Male 596/771a 734/950a
Age1 70.76 (13.52)∗b 75.17 (14.11)∗b
ICD-92 Essential tremor (333.1) - 21% (56%)∗∗∗ Constipation (564.00) - 29% (66%)∗∗∗
Anxiety state (300.00) - 20% (45%) Other malaise and fatigue (780.79) - 25% (72%)∗∗∗
Depressive disorder (311) - 14% (40%)∗ Coronary atherosclerosis (414.01) - 17% (94%)∗∗∗
Abnormality of gait (781.2) - 14% (32%)∗∗∗ Dysphagia (787.20) - 14% (77%)∗∗∗
Dystonia (333.89) - 11% (57%)∗∗∗ Abdominal pain (789.00) - 14% (90%)∗∗∗
Medication Carbidopa/Levodopa combination - 51% (51%)∗ Levodopa - 45% (57%)
Amantadine - 16% (55%)∗∗∗ Carbidopa - 45% (58%)∗∗∗
Pramipexole - 15% (59%)∗∗∗ Acetylsalicylic acid - 22% (87%)∗∗∗
Rasagiline - 14% (60%)∗∗∗ Docusate sodium - 19% (85%)∗∗∗
Selegiline - 12% (57%)∗∗∗ Vitamin D - 16% (72%)∗∗∗
Lab test Mean corpuscular hemoglobin - 3% (4%)∗∗∗ Glucose - 60% (97%)∗∗∗
Leukocytes - 3% (4%)∗∗∗ Urea nitrogen - 60% (97%)∗∗∗
Mean platelet volume - 3% (4%)∗∗∗ Creatinine - 59% (97%)∗∗∗
Width - 3% (4%)∗∗∗ Potassium - 59% (97%)∗∗∗
Erythrocytes - 3% (4%)∗∗∗ Sodium - 59% (97%)∗∗∗
CPT-4 Unlisted psychiatric service or procedure - 25% (47%) ECG; interpretation, report - 51% (95%)∗∗∗
MRI (brain, brain stem) - 13% (36%)∗∗∗ Urea nitrogen - 48% (96%)∗∗∗
Surgery - 11% (24%)∗∗∗ Creatinine - 45% (96%)∗∗∗
CT head/brain - 3% (8%)∗∗∗ Metabolic panel - 35% (98%)∗∗∗
Neuropsychological testing - 2% (36%) Echocardiography, transthoracic - 11% (97%)∗∗∗
1 Mean (standard deviation); 2 from ICD-9 on in-group and (total) percentages; a Multiple pairwise chi-squared test;
b Multiple pairwise t-test; ∗ p < 0.05, ∗ ∗ p < 0.01, ∗ ∗ ∗ p < 0.001;
CT = Computed tomography; ECG = Electrocardiogram; MRI = Magnetic resonance imaging
Supplementary Table 5: Most frequent terms for the two subgroups in the Parkinson’s disease cohort.
7
A
lz
h
e
im
e
r’
s
d
is
e
a
se
S
u
b
g
ro
u
p
I
S
u
b
g
ro
u
p
II
S
u
b
g
ro
u
p
II
I
(N
=
39
9
)
(N
=
1
,1
70
)
(N
=
1
,6
32
)
F
em
al
e/
M
al
e
3
51
/4
8∗
∗∗
a
7
9
2
/
3
7
8
∗∗
∗a
1
,2
4
9/
38
1
∗∗
∗a
A
ge
1
5
4
.4
5
(2
2
.4
8)
∗∗
b
8
4
.9
6
(9
.6
1)
∗∗
b
72
.5
1
(1
9
.7
5)
∗∗
b
IC
D
-9
2
R
ou
ti
n
e
g
y
n
ec
ol
og
ic
al
ex
am
in
a
ti
o
n
(V
7
2
.
3
1
)
-
5
3
%
(5
0%
)∗
∗∗
D
em
en
ti
a
w
/
o
b
eh
av
io
ra
l
d
is
tu
rb
a
n
ce
(2
9
4
.
1
0
)
-
39
%
(5
8
%
)∗
∗∗
C
on
st
ip
a
ti
on
(5
6
4
.
0
0
)
-
33
%
(6
1
%
)∗
∗∗
C
o
u
n
se
li
n
g
(V
6
5
.
4
0
)
-
34
%
(2
0%
)∗
∗
A
lt
er
ed
m
en
ta
l
st
a
tu
s
(7
8
0
.
9
7
)
-
2
7%
(6
8%
)∗
∗∗
A
n
x
ie
ty
st
at
e
(3
0
0
.
0
0
)
-
24
%
(6
4
%
)∗
O
st
eo
p
o
ro
si
s
(7
3
3
.
0
0
)
-
28
%
(1
7
%
)∗
∗∗
(I
v
s
II
)
P
er
si
st
en
t
m
en
ta
l
d
is
o
rd
er
s
(2
9
4
.
8
)
-
20
%
(5
2%
)∗
∗∗
D
ep
re
ss
iv
e
d
is
or
d
er
(3
1
1
)
-
2
1%
(6
4%
)
F
am
il
y
h
is
to
ry
of
os
te
o
p
or
os
is
(V
1
7
.
8
1
)
-
2
8
%
(2
1%
)∗
∗
D
y
sp
h
a
g
ia
(7
8
7
.
2
0
)
-
1
6%
(5
2
%
)∗
∗∗
D
em
en
ti
a
,
u
n
sp
.,
w
/
o
b
eh
av
io
ra
l
d
is
tu
rb
an
ce
(2
9
4
.
2
0
)
-
19
%
(6
0
%
)∗
∗∗
(I
II
v
s
II
)
M
al
ig
n
a
n
t
n
eo
p
la
sm
of
u
te
ru
s
(1
7
9
)
-
22
%
(4
5
%
)∗
∗∗
In
tr
a
cr
a
n
ia
l
h
em
o
rr
a
ge
(4
3
2
.
9
)
-
1
4%
(6
6
%
)∗
∗∗
D
em
en
ti
a
w
it
h
b
eh
av
io
ra
l
d
is
tu
rb
an
ce
(2
9
4
.
1
1
)
-
1
0%
(4
4%
)∗
∗∗
M
ed
ic
at
io
n
C
a
lc
iu
m
-
25
%
(1
2%
)∗
(I
v
s
II
I)
A
ce
ty
ls
a
li
cy
li
c
a
ci
d
-
3
9
%
(6
2
%
)∗
∗∗
D
o
n
ep
ez
il
-
25
%
(5
4%
)∗
∗∗
(I
II
v
s
I)
E
st
ra
d
io
l
-
15
%
(5
0%
)∗
∗∗
D
o
n
ep
ez
il
-
2
2
%
(3
9
%
)∗
∗(
II
v
s
I)
M
em
an
ti
n
e
-
16
%
(6
2
%
)∗
∗
Ir
on
-
11
%
(9
%
)∗
(I
v
s
II
I)
L
ev
o
fl
ox
a
ci
n
-
2
7
%
(6
7
%
)∗
∗∗
D
o
cu
sa
te
so
d
iu
m
-
16
%
(3
6
%
)∗
∗∗
N
or
et
h
is
te
ro
n
e
-
9%
(6
4%
)∗
∗∗
V
a
n
co
m
y
ci
n
-
2
4
%
(8
4
%
)∗
∗
T
ra
zo
d
on
e
-
13
%
(5
7
%
)∗
∗∗
(I
II
v
s
I)
G
ar
d
as
il
-
8%
(7
0
%
)∗
∗∗
H
a
lo
p
er
id
ol
-
2
1
%
(6
8
%
)∗
∗∗
Z
o
lp
id
em
-
9
%
(6
3%
)∗
∗∗
(I
II
v
s
I)
L
ab
te
st
C
h
la
m
y
d
ia
/
G
on
o
rr
h
o
ea
e
am
p
li
fi
ed
D
N
A
-
1
0
%
(3
7%
)∗
∗∗
M
ea
n
co
rp
u
sc
u
la
r
vo
lu
m
e
-
74
%
(5
0%
)∗
∗∗
L
eu
ko
cy
te
s
-
53
%
(5
0
%
)∗
∗∗
S
y
p
h
il
is
(r
ap
id
p
la
sm
a
re
ag
in
)
-
6%
(6
%
)∗
∗∗
C
re
a
ti
n
in
e
-
7
4
%
(5
1
%
)∗
∗∗
G
lu
co
se
-
5
3%
(5
0%
)∗
∗∗
H
IV
1
-
5%
(1
6%
)∗
∗∗
(I
v
s
II
)
E
ry
th
ro
cy
te
s
-
7
4
%
(5
0%
)∗
∗∗
E
ry
th
ro
cy
te
s
-
53
%
(5
0%
)∗
∗∗
H
ep
a
ti
ti
s
C
v
ir
u
s
ab
-
4
%
(1
1%
)
M
ea
n
co
rp
u
sc
u
la
r
h
em
o
g
lo
b
in
co
n
ce
n
tr
a
ti
on
-
7
4%
(5
0%
)∗
∗∗
H
em
a
to
cr
it
-
5
2%
(5
0
%
)∗
∗∗
H
ep
a
ti
ti
s
B
su
rf
ac
e
an
ti
ge
n
-
3%
(9
%
)
G
lu
co
se
-
7
4
%
(4
9
%
)∗
∗∗
M
ea
n
co
rp
u
sc
u
la
r
h
em
o
gl
o
b
in
co
n
ce
n
tr
at
io
n
-
5
2%
(4
9%
)∗
∗∗
C
P
T
-4
P
sy
ch
ia
tr
ic
se
rv
ic
e/
p
ro
ce
d
u
re
-
24
%
(1
7
%
)∗
∗∗
(I
v
s
II
)
E
C
G
-
7
3
%
(5
7
%
)∗
∗∗
T
S
H
-
4
4%
(6
2
%
)∗
∗
C
y
to
p
at
h
ol
o
gy
,
sl
id
es
,
ce
rv
ic
a
l/
va
g
in
al
-
1
9%
(4
4
%
)∗
∗∗
P
ar
ti
a
l
T
h
ro
m
b
o
p
la
st
in
T
im
e
T
es
t
-
6
6%
(7
2
%
)∗
∗∗
U
re
a
n
it
ro
g
en
-
4
3%
(4
9%
)∗
∗∗
M
R
I
b
ra
in
-
5%
(7
%
)∗
∗(
I
v
s
II
I)
C
re
a
ti
n
in
e
-
6
4
%
(5
3
%
)∗
∗∗
E
C
G
-
39
%
(4
2%
)∗
∗∗
C
T
p
ro
ce
d
u
re
-
5%
(4
%
)∗
∗∗
P
ro
th
ro
m
b
in
ti
m
e
-
5
6
%
(7
1
%
)∗
∗∗
P
sy
ch
ia
tr
ic
se
rv
ic
e/
p
ro
ce
d
u
re
-
22
%
(6
2
%
)∗
∗∗
(I
II
v
s
II
)
B
ra
in
im
ag
in
g
,
P
E
T
-
5%
(3
4%
)∗
∗∗
H
ea
d
C
T
-
4
5
%
(6
1
%
)∗
∗∗
H
ea
d
/b
ra
in
C
T
-
20
%
(3
8
%
)∗
∗∗
1
M
ea
n
(s
ta
n
d
a
rd
d
ev
ia
ti
o
n
);
2
fr
o
m
IC
D
-9
o
n
in
-g
ro
u
p
a
n
d
(t
o
ta
l)
p
er
ce
n
ta
g
es
;
a
M
u
lt
ip
le
p
a
ir
w
is
e
ch
i-
sq
u
a
re
d
te
st
;
b
M
u
lt
ip
le
p
a
ir
w
is
e
t-
te
st
;
∗
p
<
0
.0
5
,
∗∗
p
<
0
.0
1
,
∗∗
∗
p
<
0
.0
0
1
;
E
C
G
=
E
le
ct
ro
ca
rd
io
g
ra
m
;
a
b
=
a
n
ti
b
o
d
ie
s;
T
S
H
=
T
h
y
ro
id
-s
ti
m
u
la
ti
n
g
h
o
rm
o
n
e;
P
E
T
=
P
o
si
tr
o
n
em
is
si
o
n
to
m
o
g
ra
p
h
y
;
C
T
=
C
o
m
p
u
te
d
to
m
o
g
ra
p
h
y
;
M
R
I
=
M
a
g
n
et
ic
re
so
n
a
n
ce
im
a
g
in
g
S
u
p
p
le
m
en
ta
ry
T
ab
le
6:
M
o
st
fr
eq
u
en
t
te
rm
s
fo
r
th
e
th
re
e
su
b
gr
ou
p
s
in
th
e
A
lz
h
ei
m
er
’s
d
is
ea
se
co
h
or
t.
8
M
u
lt
ip
le
m
y
e
lo
m
a
S
u
b
g
ro
u
p
I
S
u
b
g
ro
u
p
II
S
u
b
g
ro
u
p
II
I
S
u
b
g
ro
u
p
IV
S
u
b
g
ro
u
p
V
(N
=
46
9
)
(N
=
1
3
8)
(N
=
70
3)
(N
=
23
4
)
(N
=
3
40
)
F
em
al
e/
M
al
e
23
6/
2
33
a
7
4/
6
3
a
3
36
/3
67
a
12
9/
10
5∗
∗a
1
44
/1
9
6∗
∗a
A
ge
1
69
.6
7
(1
4
.0
0
)∗
∗b
6
4
.3
8
(1
5
.2
0
)b
6
3
.4
0
(1
2
.5
7)
b
65
.3
9
(1
7
.1
0)
b
6
3.
8
6
(1
2
.3
2
)b
IC
D
-9
2
E
d
em
a
(7
8
2
.
3
)
-
53
%
(3
1%
)∗
D
is
ea
se
of
sa
li
va
ry
gl
a
n
d
s
(5
2
7
.
9
)
-
28
%
(9
%
)∗
∗∗
D
ia
rr
h
ea
(7
8
7
.
9
1
)
-
55
%
(5
8
%
)∗
∗∗
H
y
p
er
li
p
id
em
ia
(2
7
2
.
4
)
-
25
%
(1
9
%
)∗
∗∗
IV
v
s
II
/
V
O
th
in
fl
a
m
m
at
or
y
/t
ox
ic
n
eu
ro
p
a
th
y
(3
5
7
.
8
9
)
-
34
%
(2
2
%
)∗
∗
A
n
em
ia
(2
8
5
.
9
)
-
47
%
(3
1%
)∗
∗∗
D
is
or
d
er
s
of
b
o
n
e
a
n
d
ca
rt
il
a
ge
(7
3
3
.
9
9
)
-
17
%
(5
%
)∗
∗∗
N
au
se
a
(7
8
7
.
0
2
)
-
48
%
(5
6%
)∗
D
y
su
ri
a
(7
8
8
.
1
)
-
15
%
(1
3
%
)∗
(I
V
v
s
II
/
V
)
U
n
sp
in
fl
a
m
m
a
to
ry
/
to
x
ic
n
eu
ro
p
at
h
y
(3
5
7
.
9
)
-
2
4%
(1
8%
)∗
∗
S
h
or
tn
es
s
of
b
re
a
th
(7
8
6
.
0
5
)
-
4
5%
(3
1%
)∗
O
th
er
m
al
a
is
e
a
n
d
fa
ti
gu
e
(7
8
0
.
7
9
)
-
9%
(2
%
)∗
∗∗
A
n
ti
n
eo
p
la
st
ic
ch
em
ot
h
er
ap
y
(V
5
8
.
1
1
)
-
32
%
(6
7
%
)
M
a
li
gn
a
n
t
n
eo
p
la
sm
o
f
co
lo
n
(1
5
3
.
9
)
-
1
5%
(3
8%
)∗
C
o
u
n
se
li
n
g
(V
6
5
.
4
0
)
-
2
2%
(1
5%
)∗
P
le
u
ra
eff
u
si
o
n
(5
1
1
.
9
)
-
45
%
(5
8%
)∗
∗∗
O
st
eo
p
o
ro
si
s
(7
3
3
.
0
)
-
5
%
(3
%
)∗
(I
I
v
s
II
I)
N
eu
tr
op
en
ia
(2
8
8
.
0
0
)
-
2
8%
(6
7%
)∗
∗∗
N
ep
h
ri
ti
s
an
d
n
ep
h
ro
p
at
h
y
(5
8
3
.
8
1
)
-
9%
(1
0
%
)∗
(I
V
v
s
II
/
V
)
O
rg
an
/
ti
ss
u
e
tr
an
sp
la
n
t
(V
4
2
.
9
)
-
14
%
(1
1
%
)∗
∗∗
(V
v
s
II
/
II
I/
IV
)
F
ev
er
(7
8
0
.
6
0
)
-
43
%
(3
2%
)∗
∗∗
F
ra
ct
u
re
(E
8
8
7
)
-
5
%
(2
%
)∗
∗∗
(I
I
v
s
I/
II
I)
O
rg
an
/t
is
su
e
tr
an
sp
la
n
t
(V
4
2
.
9
)
-
4
2%
(6
7%
)∗
∗∗
C
h
ro
n
ic
k
id
n
ey
d
is
ea
se
(5
8
5
.
9
)
-
9
%
(1
1
%
)∗
(I
V
v
s
II
)
A
n
ti
n
eo
p
la
st
ic
ch
em
ot
h
er
ap
y
(V
5
8
.
1
1
)
-
1
2
%
(1
3%
)
M
ed
ic
a
ti
o
n
P
a
ra
ce
ta
m
ol
-
6
9%
(4
2
%
)∗
∗
V
it
a
m
in
D
-
7%
(2
%
)∗
∗
C
al
ci
u
m
-
6
6%
(5
4%
)∗
∗∗
C
al
ci
u
m
-
3
3%
(9
%
)∗
∗∗
C
a
lc
iu
m
-
42
%
(1
7
%
)∗
∗∗
S
o
d
iu
m
ch
lo
ri
d
e
-
6
5%
(4
1%
)∗
∗
O
x
y
co
d
on
e
-
7
%
(2
%
)∗
∗∗
D
ex
am
et
h
as
o
n
e
-
54
%
(5
5%
)∗
∗
V
it
am
in
D
-
2
7%
(1
3
%
)∗
∗
D
ex
am
et
h
a
so
n
e
-
2
8
%
(1
4%
)∗
∗
O
x
y
co
d
on
e
-
48
%
(3
6
%
)∗
∗∗
F
en
ta
n
y
l
-
7%
(2
%
)∗
∗∗
O
n
d
an
se
tr
on
-
5
2%
(5
6%
)∗
∗∗
C
h
ol
ec
al
ci
fe
ro
l
-
23
%
(1
4
%
)∗
B
o
rt
ez
om
ib
-
26
%
(1
7
%
)∗
∗∗
F
en
ta
n
y
l
-
4
8%
(3
9
%
)∗
∗∗
E
rg
o
ca
lc
if
er
o
l
-
6
%
(2
%
)∗
B
or
te
zo
m
ib
-
47
%
(6
4%
)∗
∗∗
E
rg
o
ca
lc
if
er
ol
-
23
%
(1
2
%
)∗
Ir
o
n
-
2
5
%
(1
7%
)∗
∗∗
H
ep
ar
in
-
48
%
(4
6%
)∗
∗∗
A
ce
ty
ls
a
li
cy
li
c
a
ci
d
8
1
m
g
-
6
%
(2
%
)∗
A
ci
cl
ov
ir
-
45
%
(6
7%
)∗
∗∗
A
to
rv
as
ta
ti
n
-
16
%
(2
7%
)∗
A
ce
ty
ls
a
li
cy
li
c
a
ci
d
81
m
g
-
23
%
(1
6
%
)∗
L
ab
te
st
E
ry
th
ro
cy
te
s
-
83
%
(2
8%
)∗
∗∗
H
em
o
gl
o
b
in
-
9%
(1
%
)∗
C
h
lo
ri
d
e
-
93
%
(4
7%
)∗
P
ro
te
in
-
2
7%
(5
%
)∗
∗∗
H
em
at
o
cr
it
-
91
%
(2
2
%
)∗
G
lu
co
se
-
83
%
(2
8%
)∗
∗∗
L
y
m
p
h
o
cy
te
s
-
8
%
(1
%
)∗
∗∗
G
lu
co
se
-
93
%
(4
6%
)∗
∗∗
G
lu
co
se
-
24
%
(4
%
)∗
∗∗
P
la
te
le
ts
-
90
%
(2
2
%
)∗
U
re
a
n
it
ro
ge
n
-
83
%
(2
8%
)∗
∗∗
L
eu
ko
cy
te
s
-
8%
(1
%
)∗
∗
P
ot
as
si
u
m
-
93
%
(4
7%
)∗
∗∗
E
ry
th
ro
cy
te
s
-
2
4%
(4
%
)∗
∗∗
E
ry
th
ro
cy
te
s
-
90
%
(2
2
%
)∗
∗∗
M
ea
n
co
rp
u
sc
u
la
r
h
em
o
gl
ob
in
-
83
%
(2
8
%
)∗
∗
M
ea
n
p
la
te
le
t
vo
lu
m
e
-
8
%
(1
%
)∗
∗
M
ea
n
co
rp
u
sc
u
la
r
h
em
o
gl
ob
in
-
93
%
(4
6%
)∗
∗
C
re
at
in
in
e
-
23
%
(4
%
)∗
∗∗
L
y
m
p
h
o
cy
te
s
-
90
%
(2
3
%
)∗
∗∗
L
eu
ko
cy
te
s
-
8
1
%
(2
7%
)∗
∗∗
(I
v
s
II
/
II
I/
IV
)
M
ea
n
co
rp
u
sc
u
la
r
h
em
og
lo
b
in
co
n
ce
n
tr
at
io
n
-
8%
(1
%
)∗
W
id
th
-
9
3%
(4
7%
)∗
∗
U
re
a
n
it
ro
g
en
-
2
1%
(4
%
)∗
∗∗
E
o
si
n
op
h
il
s
-
8
9%
(2
3%
)∗
∗∗
C
P
T
-4
B
lo
o
d
co
u
n
t
-
7
9
%
(3
3
%
)∗
∗∗
D
ia
g
n
os
ti
c/
in
te
rv
en
ti
o
n
al
C
T
-
36
%
(7
%
)∗
C
al
ci
u
m
-
7
8%
(4
6%
)∗
∗∗
C
al
ci
u
m
-
4
2%
(8
%
)∗
∗∗
G
a
m
m
ag
lo
b
u
li
n
-
63
%
(2
4
%
)∗
∗
C
al
ci
u
m
-
7
3
%
(2
8
%
)∗
∗∗
P
E
T
li
m
it
ed
a
re
a
(H
ea
d
/n
ec
k
)
-
32
%
(7
%
)∗
B
lo
o
d
co
u
n
t
-
75
%
(5
1%
)∗
∗
E
C
G
;
in
te
rp
re
ta
ti
on
,
re
p
or
t
-
3
0%
(8
%
)∗
∗∗
A
lb
u
m
in
-
60
%
(1
9
%
)∗
∗∗
E
C
G
;
in
te
rp
re
ta
ti
on
,
re
p
o
rt
-
72
%
(3
9
%
)∗
∗∗
P
E
T
-C
T
(s
k
u
ll
b
a
se
to
m
id
-t
h
ig
h
)
-
22
%
(7
%
)∗
A
lb
u
m
in
-
73
%
(4
9
%
)∗
∗∗
U
re
a
n
it
ro
g
en
-
2
8%
(6
%
)∗
∗∗
C
a
lc
iu
m
,
io
n
iz
ed
-
5
9%
(1
7%
)∗
∗∗
P
o
ta
ss
iu
m
-
71
%
(3
4%
)∗
T
u
m
o
r
im
a
gi
n
g
P
E
T
-C
T
-
1
2%
(3
9
%
)∗
∗∗
L
ac
ta
te
d
eh
y
d
ro
ge
n
as
e
-
66
%
(5
2%
)∗
∗∗
(I
II
v
s
I/
II
/
IV
)
C
h
ol
es
te
ro
l
-
15
%
(2
4
%
)∗
(I
V
v
s
I/
II
/
V
)
L
ac
ta
te
d
eh
y
d
ro
g
en
as
e
-
5
8%
(2
2
%
)∗
P
T
T
-
71
%
(4
3%
)∗
∗
C
T
th
or
ax
(n
o
co
n
tr
a
st
)
-
9%
(3
%
)∗
∗∗
B
on
e
m
ar
ro
w
;
b
io
p
sy
-
57
%
(5
9%
)∗
∗∗
U
ri
n
a
ly
si
s
-
1
2%
(9
%
)∗
∗∗
(I
V
v
s
II
I/
V
)
B
et
a
-2
m
ic
ro
g
lo
b
u
li
n
-
5
5
%
(2
6%
)∗
∗∗
1
M
ea
n
(s
ta
n
d
a
rd
d
ev
ia
ti
o
n
);
2
fr
o
m
IC
D
-9
o
n
in
-g
ro
u
p
a
n
d
(t
o
ta
l)
p
er
ce
n
ta
g
es
;
a
M
u
lt
ip
le
p
a
ir
w
is
e
ch
i-
sq
u
a
re
d
te
st
;
b
M
u
lt
ip
le
p
a
ir
w
is
e
t-
te
st
;
∗ p
<
0
.0
5
;
∗∗
p
<
0
.0
1
;
∗∗
∗ p
<
0
.0
0
1
;
E
C
G
=
E
le
ct
ro
ca
rd
io
g
ra
m
;
C
T
=
C
om
p
u
te
d
to
m
o
gr
a
p
h
y
;
P
E
T
=
P
os
it
ro
n
em
is
si
on
to
m
o
g
ra
p
h
y
;
P
T
T
=
P
ar
ti
al
tr
om
b
op
la
st
in
ti
m
e
S
u
p
p
le
m
en
ta
ry
T
ab
le
7
:
M
o
st
fr
eq
u
en
t
te
rm
s
fo
r
th
e
fi
ve
su
b
gr
ou
p
s
in
th
e
m
u
lt
ip
le
m
ye
lo
m
a
co
h
o
rt
.
9
Malignant neoplasm of prostate
Subgroup I Subgroup II
(N=6, 916) (N=1, 606)
Age1 69.64 (12.98)a 69.78 (10.56)a
ICD-92 Hyperlipidemia (272.4) - 28% (95%)∗∗∗ Nocturia (788.43) - 29% (33%)∗∗
Edema (782.3) - 24% (94%)∗∗∗ Elevated PSA (790.93) - 18% (27%)∗∗∗
Personal history of PC (V10.46) - 20% (97%)∗∗∗ Impotence of organic origin (607.84) - 18% (35%)∗∗∗
Hypertrophy (beging) of prostate (600.00) - 14% (85%)∗∗∗ Urinary frequency (788.41) - 15% (27%)∗∗∗
Hematuria (599.70) - 14% (86%)∗∗∗ Urinary hesitancy (788.64) - 11% (33%)∗∗∗
Medication Paracetamol - 44% (98%)∗∗∗ Midazolam - 17% (12%)∗∗∗
Oxycodone - 40% (98%)∗∗∗ Tadalafil - 14% (35%)∗∗∗
Ondansetron - 33% (97%)∗∗∗ Sildenafil - 12% (33%)∗∗∗
Propofol - 31% (94%)∗∗∗ Tamsulosin - 10% (12%)∗∗∗
Morphine - 30% (99%)∗∗∗ Testosterone - 8% (28%)
Lab test Glucose - 66% (96%)∗ PSA post-prostatectomy - 17% (25%)∗∗∗
Leukocytes - 63% (98%)∗ PSA free - 10% (27%)∗∗∗
Creatinine - 63% (99%)∗ Nitrite - 8% (6%)∗∗∗
Urea nitrogen - 63% (99%)∗ Leukocyte esterase - 6% (5%)∗∗∗
Potassium - 62% (99%)∗ Urine specific gravity - 6% (5%)∗∗∗
CPT-4 Calcium - 53% (98%)∗∗∗ Testosterone total - 29% (32%)∗∗∗
Anastomosis - 20% (98%)∗∗∗ Surgery - 22% (14%)∗∗∗
Ultrasound, transrectal - 7% (65%)∗∗∗ Ultrasound post-voiding residual urine/bladder capacity - 18% (29%)∗∗∗
Pelvic lymphadenectomy - 6% (100%)∗∗∗ Urinalysis - 12% (44%)∗∗∗
Cystoplasty/cystourethroplasty - 6% (100%)∗∗∗ Biopsy, prostate - 7% (31%)∗∗∗
1 Mean (standard deviation); 2 from ICD-9 on in-group and (total) percentages; a Multiple pairwise t-test; ∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001
PSA = Prostate-specific antigen
Supplementary Table 8: Most frequent terms for the two subgroups in the prostate cancer cohort.
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Malignant neoplasm of breast (female)
Subgroup I Subgroup II
(N=5, 971) (N=1, 993)
Age1 66.67 (14.27)∗a 62.86 (13.73)∗a
ICD-92 Constipation (564.00) - 25% (93%)∗ Lump or mass in breast (611.72) - 27% (29%)∗
Secondary malignant neoplasm (198.89) - 13% (93%)∗∗∗ Abnormal mammogram (793.80) - 23% (37%)∗
Acquired absence of breast/nipple (V45.71) - 12% (92%)∗∗∗ Carcinoma in situ of breast (233.0) - 15% (27%)ns
Antineoplastic chemotherapy (V58.11) - 7% (98%)∗∗∗ Family history of malignant neoplasm of breast (V16.3) - 6% (28%)
Mammogram for high-risk patient (V76.11) - 6% (63%)∗∗∗ Abnormal findings on radiological examination of breast (793.89) - 4% (36%)∗∗∗
Medication Paracetamol - 50% (92%)∗∗∗ Propofol - 27% (19%)∗∗∗
Ondansetron - 46% (87%)∗∗∗ Fentanyl - 26% (16%)∗∗∗
Fentanyl - 45% (84%)∗∗∗ Lidocaine - 25% (21%)∗∗∗
Oxycodone - 43% (91%)∗∗∗ Midazolam - 22% (18%)∗∗∗
Propofol - 40% (81%)∗∗∗ Ondansetron - 21% (13%)∗∗∗
Lab test Glucose - 67% (97%)∗∗∗ Leukocytes - 7% (3%)∗∗∗
Leukocytes - 67% (97%)∗∗∗ Glucose - 6% (3%)∗∗∗
Erythrocytes - 66% (97%)∗∗∗ Platelets - 6% (3%)∗∗∗
Hemoglobin - 65% (97%)∗∗∗ Erythrocytes - 6% (3%)∗∗∗
Hematocrit - 65% (97%)∗∗∗ Mean corpuscular hemoglobin - 6% (3%)∗∗∗
CPT-4 Surgery - 44% (81%)∗∗∗ Mammography - 35% (32%)∗∗∗
Mastectomy, partial - 33% (78%)∗ Ultrasound - 32% (27%)∗
Ultrasound - 30% (73%)∗ Surgery - 30% (19%)∗∗∗
Unlisted chemotherapy - 23% (85%)∗∗∗ Mastectomy, partial - 28% (22%)∗∗∗
Oncoprotein - 17% (85%)∗∗∗ Mammography, bilateral - 26% (39%)∗∗∗
1 Mean (standard deviation); 2 from ICD-9 on in-group and (total) percentages; a Multiple pairwise t-test; ∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001
Supplementary Table 9: Most frequent terms for the two subgroups in the breast cancer cohort.
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Parkinson’s disease (Split 2)
Subgroup I Subgroup II
(N=1, 851) (N=1, 220)
Female/Male 799/1, 051a 535/684a
Age1 71.39 (12.76)∗b 75.65 (15.25)∗b
ICD-92 Anxiety state (300.00) - 24% (65%)∗∗ Other malaise and fatigue (780.79) - 26% (53%)∗∗
Constipation (564.00) - 23% (57%)∗ Chest pain (786.50) - 22% (68%)∗∗∗
Essential tremor (333.1) - 22% (79%)∗∗ Coronary atherosclerosis (414.01) - 21% (79%)∗∗∗
Abnormality of gait (781.2) - 15% (48%)∗∗∗ Atrial fibrillation (427.31) - 17% (85%)∗∗∗
Depressive disorder (311) - 14% (53%)∗∗∗ Pleural effusion (511.9) - 17% (95%)∗∗∗
Medication Carbidopa/Levodopa combination - 49% (68%)∗∗∗ Carbidopa - 47% (43%)∗
Amantadine - 17% (74%)∗∗∗ Levodopa - 46% (42%)∗
Pramipexole - 15% (75%)∗∗∗ Acetylsalicylic acid - 26% (72%)∗∗∗
Rasagiline - 14% (78%)∗∗∗ Heparin - 23% (94%)∗∗∗
Selegiline - 12% (78%)∗∗∗ Metoprolol - 18% (81%)∗∗∗
Lab test Glucose - 9% (15%)∗∗∗ Erythrocytes - 77% (85%)∗∗∗
Leukocytes - 9% (15%)∗∗∗ Mean corpuscolar hemoglobin - 75% (86%)∗∗∗
Creatinine - 9% (15%)∗∗∗ Glucose - 75% (85%)∗∗∗
Erythrocytes - 9% (15%)∗∗∗ Width - 75% (86%)∗∗∗
Urea nitrogen - 8% (15%)∗∗∗ Leukocytes - 75% (85%)∗∗∗
CPT-4 Unlisted psychiatric service or procedure - 29% (70%)∗∗∗ Urea nitrogen - 60% (85%)∗∗∗
Surgery - 17% (48%)∗∗∗ ECG; interpretation, report - 59% (82%)∗∗∗
MRI (brain, brain stem) - 16% (58%) Urinalysis - 42% (87%)∗∗∗
CT head/brain - 5% (21%)∗∗∗ Radiologic examination, chest - 38% (86%)∗∗∗
Implanted neurostimulator - 4% (68%) Troponin, quantitative - 30% (85%)∗∗∗
1 Mean (standard deviation); 2 from ICD-9 on in-group and (total) percentages; a Multiple pairwise chi-squared test;
b Multiple pairwise t-test; ∗ p < 0.05, ∗ ∗ p < 0.01, ∗ ∗ ∗ p < 0.001;
CT = Computed tomography; ECG = Electrocardiogram; MRI = Magnetic resonance imaging
Supplementary Table 11: Most frequent terms for the two subgroups in the Parkinson’s disease second split
replication cohort.
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Malignant neoplasm of prostate (Split 2)
Subgroup I Subgroup II Subgroup III
(N=2, 703) (N=3, 846) (N=2, 096)
Age1 68.71 (12.46)a 70.92 (11.92)∗∗a 67.83 (14.49)a
ICD-92 Nocturia (788.43) - 28% (50%)∗∗∗ Personal history of PC (V10.46) - 28% (77%)∗∗∗ Palpitations (785.1) - 21% (51%)∗∗∗
Elevated PSA (790.93) - 20% (49%)∗∗∗ Hyperlipidemia (272.4) - 25% (47%)∗∗∗ Asthma (493.90) - 18% (51%)∗∗∗
Urinary frequency (788.41) - 17% (45%)∗∗∗(I vs II) Edema (782.3) - 23% (47%)∗∗∗ Vitamin D deficiency (268.9) - 15% (72%)∗∗∗
Impotence of organic origin (607.84) - 16% (52%)∗∗∗ Cardiac dysrhythmias (427.89) - 15% (69%)∗∗∗ Cyanosis (782.5) - 14% (54%)∗∗∗
Urge incontinence (788.31) - 5% (52%)∗∗∗(I vs II) Pleural effusion (511.9) - 13% (87%)∗∗∗ Neoplasm of colon (153.9) - 11% (52%)∗∗∗
Medication Midazolam - 15% (18%)∗∗∗ Paracetamol - 68% (81%)∗∗∗ Vitamin D3 - 17% (49%)∗∗∗
Tadalafil - 12% (47%)∗∗∗ Oxycodone - 61% (82%)∗∗∗ Fluticasone - 17% (61%)∗∗∗
Tamsulosin - 11% (23%)∗∗ Ondansetron - 50% (82%)∗∗∗ Atorvastatin - 17% (43%)∗∗∗
Testosterone - 8% (45%)∗∗∗(I vs II) Morphine - 50% (92%)∗∗∗ Aerosol - 15% (53%)∗∗∗
Sildenafil - 10% (44%)∗∗∗(I vs II) Lidocaine - 47% (77%)∗∗∗ Omeprazole - 10% (51%)∗∗∗
Lab test PSA total - 20% (33%)∗∗∗ Glucose - 84% (68%)∗∗∗ Glucose - 47% (21%)∗∗∗
PSA post-prostatectomy - 15% (37%)∗∗∗(I vs III) Leukocytes - 84% (72%)∗∗∗ Cholesterol - 35% (49%)∗∗∗
Nitrite - 15% (18%)∗∗∗ Urea nitrogen - 84% (72%)∗ Hemoglobin A1C - 17% (52%)∗∗∗
PSA free - 11% (47%)∗∗∗ Potassium - 84% (73%)∗∗∗(I vs III) Hepatitis C virus ab - 11% (53%)∗∗∗
Testosterone free - 6% (46%)∗∗∗(I vs II) Creatinine - 83% (72%)∗∗∗ HIV 1 - 8% (55%)∗∗∗
CPT-4 Surgery - 25% (25%)∗∗∗ Calcium - 71% (72%)∗∗∗ PSA total - 51% (23%)∗∗∗
Ultrasound post-voiding residual urine/bladder capacity - 28% (48%)∗∗∗ ECG; interpretation, report - 43% (61%)∗∗∗(II vs I) PSA free - 52% (44%)∗∗∗
Ultrasound, transrectal - 16% (57%)∗∗∗ Anastomosis - 33% (92%)∗∗∗(II vs I) ECG; interpretation, report - 41% (32%)∗∗∗(III vs I)
Urinalysis - 11% (60%)∗∗∗(I vs II) Urine culture, bacterial - 20% (69%)∗∗∗ Surgery - 34% (26%)∗∗∗(III vs I)
MRI, pelvis - 9% (43%)∗∗ Troponin, quantitative - 19% (90%)∗∗∗ Spirometry - 14% (73%)∗∗∗
1 Mean (standard deviation); 2 from ICD-9 on in-group and (total) percentages; a Multiple pairwise t-test; ∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001
PSA = Prostate-specific antigen; ab = antibodies; ECG = Electrocardiogram; MRI = Magnetic resonance imaging
Supplementary Table 14: Most frequent terms for the three subgroups in the prostate cancer second split
replication cohort.
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Malignant neoplasm of breast - female (Split 2)
Subgroup I Subgroup II
(N=5, 601) (N=2, 237)
Age1 66.98 (14.57)∗a 61.94 (13.25)∗a
ICD-92 Personal history of malignant neoplasm of breast (V10.3) - 54% (79%)∗∗∗ Lump or mass in breast (611.72) - 26% (33%)∗∗∗
Constipation (564.00) - 24% (92%)∗ Abnormal mammogram (793.80) - 22% (43%)∗∗∗
Secondary malignant neoplasm (198.89) - 14% (91%)∗∗∗ Other screening mammogram (V76.12) - 19% (44%)∗∗∗
Acquired absence of breast/nipple (V45.71) - 12% (89%)∗∗∗ Carcinoma in situ of breast (233.0) - 15% (32%)∗
Antineoplastic chemotherapy (V58.11) - 7% (99%)∗∗∗ Diffuse cystic mastopathy (610.1) - 10% (38%)∗∗∗
Medication Paracetamol - 50% (89%)∗∗∗ Propofol - 28% (23%)∗∗∗
Fentanyl - 45% (80%)∗∗∗ Fentanyl - 28% (20%)∗∗∗
Ondansetron 44% (83%)∗∗∗ Midazolam - 24% (22%)∗∗∗
Oxycodone - 42% (88%)∗∗∗ Lidocaine - 23% (23%)∗∗∗
Propofol - 38% (77%)∗∗∗ Ondansetron - 23% (17%)∗∗∗
Lab test Leukocytes - 69% (97%)∗∗∗ Leukocytes - 6% (3%)∗∗∗
Glucose - 69% (97%)∗∗∗ Glucose - 6% (3%)∗∗∗
Hematocrit - 67% (97%)∗∗∗ Width - 5% (3%)∗∗∗
Erythrocytes - 67% (97%)∗∗∗ Mean corpuscular hemoglobin concentration - 5% (3%)∗∗∗
Width - 66% (97%)∗∗∗ Erythrocytes - 5% (3%)∗∗∗
CPT-4 Surgery - 43% (79%)∗∗∗ Mammography - 33% (36%)∗∗∗
Mastectomy, partial - 34% (75%)∗∗∗ Surgery - 30% (21%)∗∗∗
Ultrasound - 27% (68%)∗∗∗ Mastectomy, partial - 28% (25%)∗∗∗
Unlisted chemotherapy - 24% (84%)∗∗∗ Ultrasound, breast(s) - 24% (40%)∗∗∗
Oncoprotein - 16% (81%)∗∗∗ Mammography, bilateral - 23% (42%)∗∗∗
1 Mean (standard deviation); 2 from ICD-9 on in-group and (total) percentages; a Multiple pairwise t-test; ∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001
Supplementary Table 15: Most frequent terms for the two subgroups in the breast cancer second split
replication cohort.
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AD = Alzheimer’s disease; ADHD = Attention deficit hyperactivity disorder; BC = Breast cancer; CD = Crohn’s disease;
MM = Multiple myeloma; PC = Prostate cancer; PD = Parkinson’s disease; T2D = Type 2 diabetes
Supplementary Figure 1: Second split Uniform Manifold Approximation and Projection (UMAP) encoding
visualization. ConvAE 1-layer CNN (a); SVD-RawCount (b); SVD-TFIDF (c); Deep Patient (d). AD =
Alzheimer’s disease; ADHD = Attention deficit hyperactivity disorder; BC = Breast cancer; CD = Crohn’s
disease; MM = Multiple myeloma; PC = Prostate cancer; PD = Parkinson’s disease; T2D = Type 2 diabetes.
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AD = Alzheimer’s disease; ADHD = Attention deficit hyperactivity disorder; BC = Breast cancer; CD = Crohn’s disease;
MM = Multiple myeloma; PC = Prostate cancer; PD = Parkinson’s disease; T2D = Type 2 diabetes
Supplementary Figure 2: Second split Uniform Manifold Approximation and Projection (UMAP) clustering
visualization. ConvAE 1-layer CNN (a); SVD-RawCount (b); SVD-TFIDF (c); Deep Patient (d). AD =
Alzheimer’s disease; ADHD = Attention deficit hyperactivity disorder; BC = Breast cancer; CD = Crohn’s
disease; MM = Multiple myeloma; PC = Prostate cancer; PD = Parkinson’s disease; T2D = Type 2 diabetes.
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Supplementary Figure 3: Complex disorder subgroups identified in the replication set. A subsample of 5, 000
patients with T2D is displayed in Figure (a).
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